Edition:
United States

Patricia Weiss

Bayer macht Rekordverlust wegen Glyphosat-Vergleich

Aug 04 2020

Frankfurt Noch nie ist Bayer so tief in die roten Zahlen gerutscht: Rückstellungen für den Glyphosat-Vergleich in den USA haben dem Leverkusener Pharma- und Agrarchemiekonzern im zweiten Quartal einen Nettoverlust von 9,5 Milliarden Euro eingebrockt.

Bayer tumbles to €9.5 billion quarterly net loss after litigation charges

Aug 04 2020

FRANKFURT German drugs and pesticides group Bayer slumped to a 9.5 billion euro ($11.2 billion) net loss in the second quarter, mainly reflecting charges to settle disputes inherited with its $63 billion takeover of Monsanto.

Bayer puts Roundup future claims settlement on hold

Jul 08 2020

FRANKFURT/NEW YORK Bayer was forced on Wednesday to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

Jul 01 2020

FRANKFURT A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

Jul 01 2020

FRANKFURT, July 1 A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

Bayer zahlt bis zu 11 Mrd Dollar in Glyphosat-Vergleich

Jun 25 2020

Frankfurt Bayer befreit sich von den Altlasten aus der Monsanto-Übernahme: Der Pharma- und Agrarchemiekonzern hat sich im Streit um den angeblich krebserregenden Unkrautvernichter Glyphosat in den USA mit einem Großteil der Kläger auf einen Vergleich geeinigt.

Bayer nears glyphosate settlement after lengthy talks: sources

Jun 23 2020

Germany's Bayer is set to reach a settlement this week with U.S. plaintiffs that claim its glyphosate-based weedkillers cause cancer, two people familiar with the matter told Reuters.

Exclusive: CureVac becomes second company to test coronavirus vaccine in Germany - sources

Jun 16 2020

FRANKFURT The unlisted biotech firm CureVac will become the second company to launch human trials of an experimental coronavirus vaccine in Germany, two people familiar with the plans told Reuters on Tuesday.

EXCLUSIVE-CureVac becomes second company to test coronavirus vaccine in Germany -sources

Jun 16 2020

* WHO says 11 experimental COVID-19 vaccines tested on humans (Adds background on CureVac financing)

EXCLUSIVE-CureVac becomes second company to test coronavirus vaccine in Germany-sources

Jun 16 2020

FRANKFURT, June 16 Unlisted biotech firm CureVac will become the second coronavirus vaccine developer to launch human trials of an experimental immunisation in Germany, two people familiar with the plans told Reuters on Tuesday.

World News